Calithera Biosciences, Inc. (CALA) Is At $6.50 Formed Wedge; Calamos Convertible & High Income Fund (CHY) Has 1.12 Sentiment

Calithera Biosciences, Inc. (NASDAQ:CALA) Logo

Calamos Convertible & High Income Fund (CHY) investors sentiment increased to 1.12 in 2017 Q4. It’s up 0.19, from 0.93 in 2017Q3. The ratio increased, as 29 investment professionals started new and increased holdings, while 26 cut down and sold their positions in Calamos Convertible & High Income Fund. The investment professionals in our database now possess: 7.66 million shares, up from 7.64 million shares in 2017Q3. Also, the number of investment professionals holding Calamos Convertible & High Income Fund in top ten holdings was flat from 0 to 0 for the same number . Sold All: 13 Reduced: 13 Increased: 19 New Position: 10.

Calithera Biosciences, Inc. (CALA) formed wedge down with $6.24 target or 4.00% below today’s $6.50 share price. Calithera Biosciences, Inc. (CALA) has $232.99M valuation. The stock increased 0.78% or $0.05 during the last trading session, reaching $6.5. About 298,043 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has declined 36.62% since May 5, 2017 and is downtrending. It has underperformed by 48.17% the S&P500.

New England Investment & Retirement Group Inc. holds 1.42% of its portfolio in Calamos Convertible and High Income Fund for 228,244 shares. Greatmark Investment Partners Inc. owns 323,825 shares or 1.39% of their US portfolio. Moreover, Dumont & Blake Investment Advisors Llc has 0.98% invested in the company for 203,588 shares. The Wisconsin-based Oarsman Capital Inc. has invested 0.21% in the stock. Meridian Investment Counsel Inc., a California-based fund reported 12,834 shares.

The stock increased 0.91% or $0.11 during the last trading session, reaching $12.19. About 214,184 shares traded. Calamos Convertible and High Income Fund (CHY) has risen 4.21% since May 5, 2017 and is uptrending. It has underperformed by 7.34% the S&P500.

Investors sentiment increased to 2.2 in 2017 Q4. Its up 0.98, from 1.22 in 2017Q3. It improved, as 10 investors sold Calithera Biosciences, Inc. shares while 20 reduced holdings. 31 funds opened positions while 35 raised stakes. 24.18 million shares or 4.20% less from 25.24 million shares in 2017Q3 were reported. Parallax Volatility Advisers Lp holds 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA) for 4,662 shares. Franklin Resource Inc reported 715,500 shares. Millennium Limited Liability owns 1.44 million shares or 0.02% of their US portfolio. State Street accumulated 527,538 shares. Landscape Mngmt Ltd Liability Corporation holds 104,034 shares. Adage Capital Prtn Grp Limited Co owns 1.50 million shares. Jpmorgan Chase And holds 6,609 shares or 0% of its portfolio. Aqr Cap Management Lc has invested 0.01% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA). Proshare Advsr Ltd Liability Corp stated it has 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA). 18,565 were accumulated by Jacobs Levy Equity Management. Geode Cap Lc reported 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). Strs Ohio holds 0% in Calithera Biosciences, Inc. (NASDAQ:CALA) or 3,600 shares. Barclays Public Ltd Limited Liability Company stated it has 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA). Wells Fargo And Mn holds 0% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA) for 62,077 shares. Retail Bank Of New York Mellon accumulated 132,678 shares.

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Calithera Biosciences had 10 analyst reports since July 24, 2015 according to SRatingsIntel. Citigroup upgraded Calithera Biosciences, Inc. (NASDAQ:CALA) rating on Friday, February 16. Citigroup has “Buy” rating and $14.0 target. The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, March 28. The company was maintained on Monday, June 12 by H.C. Wainwright. The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) earned “Buy” rating by H.C. Wainwright on Thursday, January 5. The stock of Calithera Biosciences, Inc. (NASDAQ:CALA) has “Buy” rating given on Friday, July 24 by Citigroup. Citigroup upgraded Calithera Biosciences, Inc. (NASDAQ:CALA) on Tuesday, January 24 to “Neutral” rating. The firm has “Sell” rating given on Tuesday, October 25 by Citigroup.

Calithera Biosciences, Inc. (NASDAQ:CALA) Institutional Positions Chart